
<collection>
    <source>hpo-corpus-1</source>
    <date>20250615</date>
    <key>INITIAL_CAS</key>
    <document>
        <id>INITIAL_CAS</id>
        <passage>
            <offset>0</offset>
            <sentence>
                <offset>0</offset>
                <text>﻿Case 3 was the affected sibling of Case 2.</text>
            </sentence>
            <sentence>
                <offset>44</offset>
                <text>She was born at 38 weeks of gestation via caesarean section.</text>
            </sentence>
            <sentence>
                <offset>105</offset>
                <text>Birth weight and length were 2,300 g (−2.12 SDS) and 42 cm (−3.17 SDS), respectively.</text>
            </sentence>
            <sentence>
                <offset>192</offset>
                <text>On physical examination at the age of 22 months, her weight, height, and head circumference were 7.7 kg (−3.14 SDS), 63 cm (−6.46 SDS), and 46 cm (−1.25 SDS), respectively.</text>
            </sentence>
            <sentence>
                <offset>365</offset>
                <text>Relative macrocephaly, triangular face, frontal bossing, midface hypoplasia, bulbous nose, anteverted nares, pointed, and prominent chin were observed.</text>
            </sentence>
            <sentence>
                <offset>517</offset>
                <text>She had also hyperlordosis, pes planus, prominent heels, and joint laxity.</text>
            </sentence>
            <sentence>
                <offset>592</offset>
                <text>Her neuromotor development was normal.</text>
            </sentence>
            <sentence>
                <offset>631</offset>
                <text>Her skeletal survey was found to be normal.</text>
            </sentence>
            <sentence>
                <offset>676</offset>
                <text>Serum basal GH level and peak GH responses to GH stimulation test were found to be low.</text>
            </sentence>
            <sentence>
                <offset>764</offset>
                <text>An rhGH therapy (45 μg/kg/day) was administered due to low GH levels and decreased growth velocity (3.2 cm/year, −3.56 SDS) (Table 1).</text>
            </sentence>
            <sentence>
                <offset>899</offset>
                <text>At the age of 5 years, GH therapy is still continuing, and her recent annual growth velocity was 7.6 cm.</text>
            </sentence>
            <sentence>
                <offset>1004</offset>
                <text>The baseline height SDS was −6.46, following treatment period, has decreased to −3.94.</text>
            </sentence>
        </passage>
    </document>
</collection>
